PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Blue Cross Blue Shield of NebraskaCommercial · Prior Auth · Pharmacy · NE · Oncology, Rheumatology, Infectious Disease +2 moreHigh impact

Medical/Pharmacy Policy Updates Effective 12/15/2026

Act
by Dec 15, 2026
Effective date
Dec 15, 2026
Identified
Oct 10, 2026

Summary

Blue Cross and Blue Shield of Nebraska (BCBSNE) is implementing a new medical policy (MPC X.242 OptimizeRX) effective 12/15/2026 that establishes step therapy requirements for multiple biologic medications. Preauthorization is now required for all nonpreferred products, and patients must demonstrate contraindication, intolerance, or failure to a preferred product before nonpreferred alternatives will be considered. This applies to both new and established patients across denosumab, infliximab, rituximab, tocilizumab, and trastuzumab drug classes.

Get alerts when payers change rules like this one

We check Blue Cross Blue Shield of Nebraska and other payers every day and email you when a change matches your specialty and state.

Get Blue Cross Blue Shield of Nebraska alertsPolicy Monitoring is free. No card required.

What to do

by Dec 15, 2026 · 5 steps
01Billing and prior authorization teams must implement step therapy requirements for all nonpreferred biologic products listed under policy MPC X.242 OptimizeRX in the billing system and prior authorization workflows.
02Configure the billing system to require preauthorization for all nonpreferred denosumab, infliximab, rituximab, tocilizumab, and trastuzumab products (HCPCS codes Q5121, Q5103, Q5104, Q5119, Q5115, Q5123, Q5135, Q5156, Q5117, Q5116, Q5113, Q5114, Q5112, Q5162, Q5136, Q5157, Q5161, Q5167, Q5171, Q5166, Q5173, Q5159, J0897, J1745, J9312, J9311, J3262, J3590, J9355, J9356).
03Update prior authorization request templates to require documentation of patient contraindication, intolerance, or prior failure to preferred products before approval of nonpreferred alternatives.
04Train front-desk, billing, and clinical staff on the new step therapy workflow for both new-start and established patients.
05Verify BCBSNE claims submission processes reflect the new preauthorization mandate to avoid claim denials.
If missed: Failure to implement preauthorization will result in claim denials for nonpreferred biologic products.

Codes mentioned

J0897J1745J9312J9311J3262J3590J9355J9356Q5121Q5103Q5104Q5119Q5115Q5123Q5135Q5156Q5117Q5116Q5113Q5114Q5112Q5162Q5136Q5157Q5161Q5167Q5171Q5166Q5173Q5159

Original notice

Medical/Pharmacy Policy Updates Effective 12/15/2026
nebraskablue.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account